A method for producing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer, such as compound 1 and compound 2 is disclosed. The method proceeds through an O-allylated tyrosine-based compound, such as compound 3 and preferably comprises [3,3] sigmatropic Claisen rearrangement and olefin cross metathesis reactions. In addition, a pharmaceutical composition comprising a compound of formula (I) a tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and a pharmaceutically acceptable carrier or excipient is disclosed.
本发明公开了一种制备式(I)化合物或其药学上可接受的盐、溶剂化物、互变异构体或立体异构体的方法,例如化合物1和化合物2。该方法通过一种O-烯丙基化的基于
酪氨酸的化合物,例如化合物3进行,最好包括[3,3]sigmatropic Claisen重排和烯烃交叉重聚反应。此外,本发明还公开了一种包含式(I)化合物、肿瘤坏死因子(TNF)相关的凋亡诱导
配体(
TRAIL)和药学上可接受的载体或赋形剂的制药组合物。